STAAR Surgical Q2 net sales more than double on growth in China, Asia-Pacific, Americas
STAA•Analyst expectations and valuation
The company reported second-quarter sales of $90 million versus a consensus estimate of $90.26 million from nine analysts.
The current average analyst rating on the shares is "hold," with 3 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for STAAR Surgical Co is $29.00, about 1.8% above its July 15 closing price of $28.50. The stock recently traded at 66 times the next 12-month earnings versus a P/E of 1,353 three months ago.
Outlook and operational challenges
STAAR Surgical said persistent geopolitical and macroeconomic headwinds could negatively affect future sales growth.
The company said it is focused on resolving remaining ERP system issues in the third quarter of 2026 and maintained its 2026 strategic objectives of revenue growth, profit expansion and innovation acceleration.
Q2 sales more than double on China and Asia-Pacific growth
STAAR Surgical said preliminary second-quarter net sales more than doubled year over year, slightly missing analyst expectations, as growth in China, broader Asia-Pacific and double-digit gains in the Americas drove results.
The company said sales in the Middle East and parts of EMEA and Asia-Pacific were negatively affected by geopolitical and macroeconomic headwinds. It also said distributor inventory in China returned to targeted levels after prior excess had suppressed sales.
